ASPIRA
Aspira Pathlab & Diagnostics financials
- Market cap
- ₹94 Cr
Quarterly results
Q1 FY26: revenue up 13.1%, net profit up 740.0% against the same quarter last year.
| Line item | Q1 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 3 | 4 | 5 | 6 | 5 +108% | 6 +51% | 5 +13% |
| EBITDA | -0 | -0 | 0 | 1 | 1 +243% | 1 +538% | 1 +162% |
| Net profit | -1 | -0 | 0 | 1 | 0 +143% | 1 +236% | 0 +740% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +45.9% 1Y
1Y: ₹64.83 on 9 Sept 2025 → ₹94.56. High ₹133.29 (29 May 2026), low ₹54 (18 Mar 2026).
Financials, as filed
| Year ending | FY25 |
|---|---|
| Revenue | ₹22 Cr |
| Operating profit | ₹3 Cr |
| Operating margin | 13.9% |
| Interest | ₹0 Cr |
| Depreciation | ₹2 Cr |
| Net profit | ₹2 Cr |
| Net margin | 9.2% |
| Cash from operations | ₹2 Cr |
| Free cash flow | ₹2 Cr |
| ROCE | 17.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY24 | FY25 |
|---|---|---|
| Equity capital | ₹10 Cr | ₹10 Cr |
| Reserves | ₹-5 Cr | ₹-3 Cr |
| Borrowings | ₹8 Cr | ₹8 Cr |
| Other liabilities | ₹2 Cr | ₹2 Cr |
| Total liabilities | ₹15 Cr | ₹17 Cr |
| Fixed assets | ₹7 Cr | ₹7 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr |
| Other assets | ₹8 Cr | ₹11 Cr |
| Total assets | ₹15 Cr | ₹17 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public trimmed −28.21 pp while promoters added +28.19 pp. The shareholder count shrank 8% to 1,620.
- Promoters
- 46.6%
- Public
- 53.4%
Since Jun 2025
- Public −28.21 pp
- Promoters +28.19 pp
How it drifted, 12 quarters
Over this window the public fell from 81.1% to 53.4% — −27.7 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 18.9%, Public 81.1%.Dec '23: Promoters 18.9%, Public 81.1%.Mar '24: Promoters 18.7%, Public 81.3%.Jun '24: Promoters 18.7%, Public 81.3%.Sep '24: Promoters 18.6%, Public 81.5%.Dec '24: Promoters 18.6%, Public 81.5%.Mar '25: Promoters 18.4%, Public 81.6%.Jun '25: Promoters 18.4%, Public 81.6%.Sep '25: Promoters 18.4%, Public 81.6%.Dec '25: Promoters 18.4%, Public 81.6%.Mar '26: Promoters 18.4%, Public 81.6%.Jun '26: Promoters 46.6%, Public 53.4%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Raj Arvind Bhanushali +6.21 pp 6.97% held
- Arvind Karsandas Bhanushali +5.19 pp 13.79% held
- Jay Arvind Bhanushali +4.97 pp 7.23% held
- Nikunj Velji Mange +4.97 pp 7.11% held
- Investeria Financial Services Private Limited newly disclosed 1.80% held
- Deepali Arvind Bhanushali +0.83 pp 9.43% held
- Ruxmani Jayant Bhansali newly disclosed 0.16% held
The same filing shows 0 holders trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Aspira Pathlab & Diagnostics Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Arvind Karsandas Bhanushali | 13.79% | +5.19 pp |
| Deepali Arvind Bhanushali | 9.43% | +0.83 pp |
| Aditya Agrawal | 7.39% | unchanged |
| Jay Arvind Bhanushali | 7.23% | +4.97 pp |
| Nikunj Velji Mange | 7.11% | +4.97 pp |
| Raj Arvind Bhanushali | 6.97% | +6.21 pp |
| Rajesh Premji Bhanushali | 5.52% | unchanged |
| Pankaj Jashwant Shah | 4.86% | unchanged |
| Pooja Rajesh Bhanushali | 3.60% | unchanged |
| Manas Modi | 3.36% | unchanged |
| Amit Modi | 2.92% | unchanged |
| Amit Modi Huf | 2.82% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Aspira Pathlab & Diagnostics Limited
Guides on how to read this kind of business and the numbers that matter.